[{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"PB2452","moa":"P2Y12 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SFJ Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.12,"dosageForm":"","sponsorNew":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Bilim Pharmaceuticals","sponsor":"H&T Presspart","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Bilim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Dry Powder Inhaler","sponsorNew":"Bilim Pharmaceuticals \/ Bilim Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bilim Pharmaceuticals \/ Bilim Pharmaceuticals"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SFJ Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"intravenous infusion","sponsorNew":"SFJ Pharmaceuticals \/ SFJ","highestDevelopmentStatusID":"7","companyTruncated":"SFJ Pharmaceuticals \/ SFJ"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Nemera","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Ache","highestDevelopmentStatusID":"12","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Ache"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Approved","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ MSRD","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ MSRD"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bentracimab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Bentracimab","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SFJ Pharmaceuticals \/ SERB","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ SERB"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Celmatix","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Ache Laboratorios Farmaceuticos SA"}]

Find Clinical Drug Pipeline Developments & Deals by Huhtamaki

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 08, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Recipient : Celmatix

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SE...

                          Brand Name : PB2452

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 11, 2023

                          Lead Product(s) : Bentracimab

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Serb

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : PB2452 (bentracimab) is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

                          Brand Name : PB2452

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 17, 2023

                          Lead Product(s) : Bentracimab

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Recipient : PhaseBio Pharmaceuticals

                          Deal Size : $120.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.

                          Brand Name : ACH000029

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 24, 2021

                          Lead Product(s) : ACH000029

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : McQuade Center for Strategic Research and Development

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : In the study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin.

                          Brand Name : Empaveli

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          May 14, 2021

                          Lead Product(s) : Pegcetacoplan

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Recipient : Apellis Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually aft...

                          Brand Name : Clilon

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 06, 2021

                          Lead Product(s) : Ketorolac Trometamol

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Recipient : Nemera

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration between SFJ and Nektar will support a new Phase 2/3 registrational clinical study of BEMPEG plus pembrolizumab in patients with head and neck cancer whose tumors express PD-L1 (Combined Positive Score).

                          Brand Name : NKTR-214

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 17, 2021

                          Lead Product(s) : Bempegaldesleukin,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Nektar Therapeutics

                          Deal Size : $150.0 million

                          Deal Type : Collaboration

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration will support Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix, a formulation of Budesonide Formoterol for Asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).

                          Brand Name : Ventofor

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 01, 2020

                          Lead Product(s) : Budesonide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Recipient : H&T Presspart

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 10, 2020

                          Lead Product(s) : PB2452

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Recipient : PhaseBio Pharmaceuticals

                          Deal Size : $120.0 million

                          Deal Type : Collaboration

                          blank